Genital Herpes Vaccine
"MTS22 – David Knipe – Herpes Simplex Virus 2 (HSV-2)," Meet The Scientist, March 31,2009, Podcast
"Findings Recommend Herpes Vaccine for Human Trials," Focus, January 14, 2005.
"Herpes Vaccine Developed at HMS Licensed for Preclinical Trials", Focus, March 7, 2008.
"Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School", Press Release, February 25, 2008
“Sanofi Pasteur Completes the Acquisition of Acambis”, Press Release, September 25, 2008
How can you help our genital herpes vaccine research?
Thank you for your interest in making a gift to the Knipe Lab Research Fund.
Your gift can be made using the secure online gift form available at:
This form is also available at “Giving to HMS” in the Resources section on the HMS homepage.
Once in the gift form, please select “Harvard Medical School” from the drop-down list of schools and then from the drop-down list of Funds, please select “Friends of Harvard Medicine”. To ensure that your gift is directed to the Knipe Lab, please type “Knipe Lab Research Fund (520-362612)” in the “Comments/Other Designation” section of the form. Your gift will then be directed to the Knipe Lab Research Fund.
I would like to take this opportunity to thank you for your generous support of our research.
Publications on the Vaccine
Da Costa, X.J., C.A. Jones and D.M. Knipe. 1999. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proceedings of the National Academy of Sciences, USA 96:6994-6998. (pdf)
Da Costa, X.J., M.F. Kramer, J. Zhu, M.A. Brockman and D.M. Knipe. 2000. Construction, phenotypic analysis and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. Journal of Virology 74:7963-7971. (pdf)
Hoshino, Y., S.K. Dalai, K. Wang, L. Pesnicak, T.Y. Lau, D.M. Knipe, J.I. Cohen, and S.E. Straus. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 79:410-418. (pdf)
Dudek, T. and D. M. Knipe. 2006. Replication-defective viruses as vaccines and vaccine vectors. Virology. 344: 230-239. This paper reviews the use of replication-defective viruses as vaccines. (pdf)
van Lint, A.L., E. Torres-Lopez, D.M. Knipe. 2007. Immunization with a replication-defective herpes simplex virus-2 mutant reduces herpes simplex virus-1 infection and prevents ocular disease. Virology. 368: 227-31. This paper shows that dl5-29 can protect mice against HSV-1 infection also. (pdf)
Dudek, T., L. Mathews, D.M. Knipe. 2007. Disruption of the UL41 Gene in the Herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology. 372:165-75. (pdf)
Hoshino, Y., L. Pesnicak, K.C. Dowdell, J. Lacayo, T. Dudek, D.M. Knipe, S.E. Straus, J.I. Cohen. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine. 26: 4034-40. (pdf)